Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENETIC-AF
NCT01970501Phase 2Completed
- Sponsor
- Oruka Therapeutics
- Start
- Apr 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of bucindolol in Atrial fibrillation (AFib), atrial flutter (AFL), sponsored by Oruka Therapeutics. Started Apr 2014; status: completed.
02
Drugs
bucindolol
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT01970501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01970501.